CERo Therapeutics Holdings, Inc.
CERO · OTC · United States
Share price · CERO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CERO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Jul 2026+54.5%
Nothing announced by CERO that day or the session before.
- 10 Jun 2026+27.3%
Nothing announced by CERO that day or the session before.
- 19 May 2026-25.9%
Nothing announced by CERO that day or the session before.
- 6 May 2026+47.8%
Nothing announced by CERO that day or the session before.
- 5 May 2026-23.3%
Nothing announced by CERO that day or the session before.
- 4 May 2026-11.8%
- 4 Dec 2025+36.1%
Nothing announced by CERO that day or the session before.
- 3 Nov 2025+70.4%
Nothing announced by CERO that day or the session before.
- 30 Oct 2025-94.7%
- 21 Oct 2025-16.3%
Nothing announced by CERO that day or the session before.
Share of unusual movement by asset
For each asset, the share of CERO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
CER-1236events and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 27% |
| Other company news (earnings, financing, releases naming no asset) | — | 16% |
| Sessions with no dated event | — | 57% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Tim4 ligand (phosphatidylserine displayed on tumor cell surface)Cell therapy | Acute Myeloid Leukemia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $2.0M | $0.7M | —-$3.0M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $1.7M | $0.9M | $1.0M-$7.9M operating cash flow | report ↗ |
| 2026-Q1 | — | $2.3M | $0.9M | $5.9M$2.8M operating cash flow | report ↗ |
| 2025-Q3 | — | $2.4M | $2.0M | $4.9M-$3.2M operating cash flow | report ↗ |
| 2025-Q2 | — | $2.8M | — | $5.4M | report ↗ |
| 2025-Q1 | — | $2.9M | — | $5.1M | report ↗ |
| 2024-Q3 | — | $1.8M | $3.4M | $4.2M | report ↗ |
| 2024-Q2 | — | $2.7M | $3.6M | $2.5M | report ↗ |
| 2023-Q3 | — | $1.3M | $0.1M | $0.3M-$0.3M operating cash flow | report ↗ |
| 2023-Q2 | — | $1.2M | $0.1M | $1.4M-$0.9M operating cash flow | report ↗ |
| 2023-Q1 | — | $1.8M | $0.2M | $0.5M-$0.2M operating cash flow | report ↗ |
| 2022-Q3 | — | — | $0.5M | —-$0.2M operating cash flow | report ↗ |
| 2022-Q2 | — | — | $0.6M | $0.1M-$0.2M operating cash flow | report ↗ |
| 2022-Q1 | — | — | $0.8M | $0.4M-$0.3M operating cash flow | report ↗ |
| 2021-Q3 | — | — | $0 | —$0 operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $1.7M | $5.0M-$16M operating cash flow | report ↗ |
For fiscal year 2025, CERo Therapeutics reported no disclosed revenue or R&D spend. Cash and equivalents totaled $1.66M, with a net loss of $19.92M and quarterly net burn of $19.92M.
The company’s narrative centered on its lead candidate CER-1236. The FDA cleared an IND for acute myeloid leukemia after an earlier clinical hold, and a second IND was accepted for non-small cell lung cancer and ovarian cancer. A Phase 1 AML trial began in May 2025, with four patients completing dose-limiting toxicity monitoring without treatment-related toxicities and a fifth patient dosed in March 2026. CER-1236 received Orphan Drug Designation in July 2025 and Fast Track Designation in September 2025, and the trial was expanded to include MDS and myelofibrosis. The filing also disclosed Nasdaq delisting, substantial doubt about going concern, and multiple financing arrangements.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-03-04 | Francois Eric · director | Award / grant (derivative) | 1,823,278 | — | — | Form 4 |
| 2026-01-07 | KUCHARCHUK ANDREW ALBERT · Chief Financial Officer | Award / grant (derivative) | 1,162,099 | — | — | Form 4 |
| 2026-01-07 | Byrnes Michael · director | Award / grant (derivative) | 690,900 | — | — | Form 4 |
| 2026-01-07 | Ehrlich Christopher B · director, Chairman and CEO | Award / grant (derivative) | 4,530,997 | — | — | Form 4 |
| 2026-01-07 | ATWOOD BRIAN G · director | Award / grant (derivative) | 1,612,099 | — | — | Form 4 |
| 2026-01-07 | Patel Shami · director | Award / grant (derivative) | 690,900 | — | — | Form 4 |
| 2026-01-07 | Pierce Kristen · Chief Development Officer | Award / grant (derivative) | 1,612,099 | — | — | Form 4 |
| 2026-01-07 | LAPORTE KATHLEEN · director | Award / grant (derivative) | 690,900 | — | — | Form 4 |